The expansion is effective immediately, nearly one year after NeuroStar ® Advanced Therapy received FDA clearance as the first first-line add-on treatment for adolescents aged 15-21 with MDD. In the ...

The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato (esketamine), as a ...

Data from the study showed that treatment with Spravato alone led to a rapid and superior improvement in the Montgomery-Asberg Depression Rating Scale (MADRS) total score compared to placebo.

In the ESCAPE-TRD study, Spravato outperformed quetiapine on the main endpoint of achieving remission at eight weeks, measured by the Montgomery-Åsberg Depression Rating Scale (MADRS), with rates ...

Spravato is the first ketamine-based medicine approved to treat depression, and also the first of a new class of glutamate NMDA receptor-targeting drugs that have ended a decades-long drought at ...

In terms of the newest collaboration, the health care professionals said they decided that having all the services under one ...

Jessica Mendoza: Sean has what's called treatment-resistant depression, and a few years ago he found out about a new kind of treatment that might help him. It's called Spravato, and it's made by ...

Tesla and SpaceX CEO Elon Musk clarified that he uses only "a small amount once every other week or something like that" ...

Johnson & Johnson will stop late-stage studies of its experimental drug to treat major depressive disorder due to a lack of sufficient efficacy, the drug and medical device maker said on Thursday.

Two cutting edge treatments for though-to-treat major depression are remarkably successful: TMS Therapy and Spravato (Esketamine) treatment. TMS is safe, medication free and covered by insurance.

Spravato (esketamine) is prescribed for adults to treat: major depressive disorder (MDD), also called depression, with suicidal thoughts or actions treatment-resistant depression For MDD ...